These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 30610833)

  • 1. Artificially low mild cognitive impairment to normal reversion rate in the Alzheimer's Disease Neuroimaging Initiative.
    Thomas KR; Eppig JS; Weigand AJ; Edmonds EC; Wong CG; Jak AJ; Delano-Wood L; Galasko DR; Salmon DP; Edland SD; Bondi MW;
    Alzheimers Dement; 2019 Apr; 15(4):561-569. PubMed ID: 30610833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MCI-to-normal reversion using neuropsychological criteria in the Alzheimer's Disease Neuroimaging Initiative.
    Thomas KR; Edmonds EC; Eppig JS; Wong CG; Weigand AJ; Bangen KJ; Jak AJ; Delano-Wood L; Galasko DR; Salmon DP; Edland SD; Bondi MW;
    Alzheimers Dement; 2019 Oct; 15(10):1322-1332. PubMed ID: 31495605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is there an MCI reversion to cognitively normal? Analysis of Alzheimer's disease biomarkers profiles.
    Park MH; Han C
    Int Psychogeriatr; 2015 Mar; 27(3):429-37. PubMed ID: 25255915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuropsychological criteria for mild cognitive impairment improves diagnostic precision, biomarker associations, and progression rates.
    Bondi MW; Edmonds EC; Jak AJ; Clark LR; Delano-Wood L; McDonald CR; Nation DA; Libon DJ; Au R; Galasko D; Salmon DP
    J Alzheimers Dis; 2014; 42(1):275-89. PubMed ID: 24844687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early versus late MCI: Improved MCI staging using a neuropsychological approach.
    Edmonds EC; McDonald CR; Marshall A; Thomas KR; Eppig J; Weigand AJ; Delano-Wood L; Galasko DR; Salmon DP; Bondi MW;
    Alzheimers Dement; 2019 May; 15(5):699-708. PubMed ID: 30737119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic and Prognostic Value of the Combination of Two Measures of Verbal Memory in Mild Cognitive Impairment due to Alzheimer's Disease.
    Sala I; Illán-Gala I; Alcolea D; Sánchez-Saudinós MB; Salgado SA; Morenas-Rodríguez E; Subirana A; Videla L; Clarimón J; Carmona-Iragui M; Ribosa-Nogué R; Blesa R; Fortea J; Lleó A
    J Alzheimers Dis; 2017; 58(3):909-918. PubMed ID: 28527215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statistically Derived Subtypes and Associations with Cerebrospinal Fluid and Genetic Biomarkers in Mild Cognitive Impairment: A Latent Profile Analysis.
    Eppig JS; Edmonds EC; Campbell L; Sanderson-Cimino M; Delano-Wood L; Bondi MW;
    J Int Neuropsychol Soc; 2017 Aug; 23(7):564-576. PubMed ID: 28578726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Transition of Mild Cognitive Impairment Over Time: An AV45- and FDG-PET Study of Reversion and Conversion Phenomena.
    Ashraf-Ganjouei A; Moradi K; Faghani S; Abdolalizadeh A; Khomeijani-Farahani M; Fatehi F; Alzheimer's Disease Neuroimaging Initiative
    Curr Alzheimer Res; 2021; 18(9):721-731. PubMed ID: 34819007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies.
    Podhorna J; Krahnke T; Shear M; Harrison JE;
    Alzheimers Res Ther; 2016 Feb; 8():8. PubMed ID: 26868820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Associations of circulating saturated long-chain fatty acids with risk of mild cognitive impairment and Alzheimer's disease in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort.
    Fan L; Borenstein AR; Wang S; Nho K; Zhu X; Wen W; Huang X; Mortimer JA; Shrubsole MJ; Dai Q;
    EBioMedicine; 2023 Nov; 97():104818. PubMed ID: 37793213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.
    Egli SC; Hirni DI; Taylor KI; Berres M; Regeniter A; Gass A; Monsch AU; Sollberger M
    J Alzheimers Dis; 2015; 44(2):625-33. PubMed ID: 25322924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Susceptibility of the conventional criteria for mild cognitive impairment to false-positive diagnostic errors.
    Edmonds EC; Delano-Wood L; Clark LR; Jak AJ; Nation DA; McDonald CR; Libon DJ; Au R; Galasko D; Salmon DP; Bondi MW;
    Alzheimers Dement; 2015 Apr; 11(4):415-24. PubMed ID: 24857234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
    Mathys J; Gholamrezaee M; Henry H; von Gunten A; Popp J
    Exp Gerontol; 2017 Dec; 100():45-53. PubMed ID: 29054536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
    Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
    Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Longitudinal Study of Total and Phosphorylated α-Synuclein with Other Biomarkers in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment.
    Wang H; Stewart T; Toledo JB; Ginghina C; Tang L; Atik A; Aro P; Shaw LM; Trojanowski JQ; Galasko DR; Edland S; Jensen PH; Shi M; Zhang J;
    J Alzheimers Dis; 2018; 61(4):1541-1553. PubMed ID: 29376878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimating Alzheimer's Disease Progression Rates from Normal Cognition Through Mild Cognitive Impairment and Stages of Dementia.
    Davis M; O Connell T; Johnson S; Cline S; Merikle E; Martenyi F; Simpson K
    Curr Alzheimer Res; 2018; 15(8):777-788. PubMed ID: 29357799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study.
    Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Li QX; Ames D; Masters CL; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM;
    J Alzheimers Dis; 2018; 66(3):1193-1211. PubMed ID: 30412495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative.
    Grill JD; Di L; Lu PH; Lee C; Ringman J; Apostolova LG; Chow N; Kohannim O; Cummings JL; Thompson PM; Elashoff D;
    Neurobiol Aging; 2013 Jan; 34(1):62-72. PubMed ID: 22503160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease.
    Portelius E; Zetterberg H; Skillbäck T; Törnqvist U; Andreasson U; Trojanowski JQ; Weiner MW; Shaw LM; Mattsson N; Blennow K;
    Brain; 2015 Nov; 138(Pt 11):3373-85. PubMed ID: 26373605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal Fluid Biomarkers and Clinical Progression in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment.
    Wolfsgruber S; Polcher A; Koppara A; Kleineidam L; Frölich L; Peters O; Hüll M; Rüther E; Wiltfang J; Maier W; Kornhuber J; Lewczuk P; Jessen F; Wagner M
    J Alzheimers Dis; 2017; 58(3):939-950. PubMed ID: 28527210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.